EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.

Joyce Hoi-Sze You William Chi Shing ChoWai-Kit MingYu-Chung LiChung-Kong KwanKwok-Hung AuJoseph Siu-Kie Au

Published in: PloS one (2021)

EGFR mutation-guided erlotinib appears to be the cost-effective strategy from the perspective of Hong Kong public healthcare provider over a broad range of WTP.

Keyphrases

epidermal growth factor receptor
advanced non small cell lung cancer
healthcare
tyrosine kinase
small cell lung cancer
primary care
mental health